NASDAQ:DXR Daxor (DXR) Stock Price, News & Analysis $7.45 -0.59 (-7.34%) Closing price 11/20/2026 03:57 PM EasternExtended Trading$7.35 -0.10 (-1.29%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Daxor Stock (NASDAQ:DXR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Daxor alerts:Sign Up Key Stats Today's Range$6.94▼$8.0050-Day Range$7.45▼$11.7252-Week Range$6.94▼$14.76Volume33,829 shsAverage Volume12,280 shsMarket Capitalization$43.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview Daxor Corporation is a medical technology company focused on blood-volume measurement and personalized blood management. Founded in 1970, the company develops diagnostic tools intended to help clinicians assess a patient’s blood volume and support treatment decisions. Its flagship product, the BVA-100 Blood Volume Analyzer, is an FDA-cleared system that measures total blood volume as well as red blood cell and plasma volumes. The system is designed for use in clinical settings, where these measurements can help inform care for patients with conditions such as heart failure and other fluid-management challenges. Daxor’s products and related services are directed primarily at healthcare providers and medical institutions. The company’s work centers on making blood-volume analysis available as a clinical tool to support individualized patient care.AI Generated. May Contain Errors. Read More Daxor Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreDXR MarketRank™: 2.682892906815 of 5 starsDaxor scored higher than 54% of companies evaluated by MarketBeat, and ranked 693rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingModerate Buy Consensus RatingDaxor has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDaxor has only been the subject of 1 research reports in the past 90 days.Read more about Daxor's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Daxor has been sold short.Short Interest Ratio / Days to CoverDaxor has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daxor has recently decreased by 69.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDaxor does not currently pay a dividend.Dividend GrowthDaxor does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.46 News SentimentDaxor has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Daxor this week, compared to 1 article on an average week. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $8,030.00 in company stock, which represents 0.0185% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Daxor insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,030.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders51.50% of the stock of Daxor is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.34% of the stock of Daxor is held by institutions.Read more about Daxor's insider trading history. Receive DXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DXR Stock News HeadlinesDaxor Secures Expanded BVA Adoption Across Major Memphis Health System; Stock DownNovember 18 at 1:20 PM | rttnews.comMajor Memphis Health System Expands BVA® Adoption to New Hospital Outpatient SiteNovember 18 at 8:00 AM | globenewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 21 at 1:00 AM | Porter & Company (Ad)Daxor Expands Midwest Footprint with Launch of ezBVA Lab Program at Premier Kansas Academic Medical CenterNovember 17, 2026 | finance.yahoo.comDaxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26October 15, 2026 | globenewswire.comDaxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026October 14, 2026 | globenewswire.comDaxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026October 13, 2026 | globenewswire.comDaxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026October 1, 2026 | globenewswire.comSee More Headlines DXR Stock Analysis - Frequently Asked Questions How have DXR shares performed this year? Daxor's stock was trading at $14.75 at the start of the year. Since then, DXR stock has decreased by 49.5% and is now trading at $7.45. How do I buy shares of Daxor? Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Daxor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Daxor investors own include Micron Technology (MU), Alibaba Group (BABA), 3D Systems (DDD), D.R. Horton (DHI), FTI Consulting (FCN), Kinross Gold (KGC) and Applied Digital (APLD). Company Calendar Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DXR's financial health is in the Red zone, according to TradeSmith. DXR has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:DXR Previous SymbolNYSEAMERICAN:DXR CIK27367 Webwww.daxor.com Phone212-244-0555Fax212-244-0806Employees37Year Founded1970Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares5,840,000Free Float2,831,000Market Cap$43.51 million OptionableNot Optionable Beta0.43 Social Links 7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and GoogleCould the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.Get This Free Report This page (NASDAQ:DXR) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.